Diagnostic Development Expertise

Developing diagnostics to support treatment decisions across the therapeutic spectrum

A sensitive and specific diagnostic can pinpoint a disease or monitor the efficacy of a line of treatment. Yet diagnostics developers face unique challenges, from regulatory pathways to reimbursement hurdles. Count on Premier Research to guide you through them.

We’ve conducted successful studies for in vitro diagnostics and lab-developed tests—including point-of-care diagnostics, molecular diagnostics, immunoassays, and sample collection devices. While we work across various therapeutic areas, we provide specific expertise in oncology, infectious disease, women’s health, and gastrointestinal disease. In fact, our diagnostics franchise managed the first successful premarket approval of a colorectal cancer diagnostic that led to the only FDA-approved stool-DNA noninvasive colorectal cancer screening test. That’s just one example of how Premier Research conquers the complexities of developing novel diagnostics.

• Customized services, scalable solutions. We work on diagnostic trials of all kinds—regardless of size, stage, setting, or data type—with clients of every size, serving as an extension of your development team. We approach each project with flexibility, then tailor solutions that help accelerate your development.
• Experienced clinical staff. From the project managers and clinical research associates who staff your study to the KOLs throughout our site network, you will partner with medical and procedural experts who can provide insights and help eliminate roadblocks.
• Proven track record. With proven expertise in all manner of studies— PMA; 510k equivalence, de novo, point of care; and dual 510k/CLIA submissions—we are prepared to answer your FDA-related questions, review and support submissions, and analyze your protocols, your competitors, and your data verification. In short, we are ready to be your partner.
• Demonstrated speed to start-up. With a global network of sites with which we regularly partner, we can often waive the pre-study visit, accelerating timelines and lowering costs.

×